Key Insights

Highlights

Treatment Research

2 treatments under study, led by Petct

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05255926Not ApplicableRecruitingPrimary

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

Showing all 1 trials

Research Network

Common Treatments

  • Petct1
  • 68gapentixafor1

Active Sponsors

  • Zhongnan Hospital1

Top Investigators

Related Conditions

  • Petct1
  • Hematological Malignancy1

Activity Timeline